Screener
Stoke Therapeutics, Inc. STOK Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income (expense), net | 3,397 | 2,889 |
| Other income | 18 | 28 |
| Total other income (expense) | 3,415 | 2,917 |
| (Loss) income before income taxes | $(50,003) | $114,157 |
| Provision for income taxes | — | 1,278 |
| Net (loss) income | $(50,003) | $112,879 |
| Net (loss) income per share: | ||
| Basic | $(0.79) | $1.95 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s pre-tax income?
- Stoke Therapeutics, Inc. (STOK) reported pre-tax income of -$50M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s pre-tax income changed year-over-year?
- Stoke Therapeutics, Inc.'s pre-tax income decreased by 143.8% year-over-year, from $114.16M to -$50M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Stoke Therapeutics, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude